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Transmission of scrapie prions to 
primate after an extended silent 
incubation period
Emmanuel E. Comoy1, Jacqueline Mikol1, Sophie Luccantoni-Freire1, Evelyne Correia1, 
Nathalie Lescoutra-Etchegaray1, Valérie Durand1, Capucine Dehen1, Olivier Andreoletti2, 
Cristina Casalone3, Juergen A. Richt4,†, Justin J. Greenlee4, Thierry Baron5, 
Sylvie L. Benestad6, Paul Brown1 & Jean-Philippe Deslys1
Classical bovine spongiform encephalopathy (c-BSE) is the only animal prion disease reputed to be 
zoonotic, causing variant Creutzfeldt-Jakob disease (vCJD) in humans and having guided protective 
measures for animal and human health against animal prion diseases. Recently, partial transmissions 
to humanized mice showed that the zoonotic potential of scrapie might be similar to c-BSE. We here 
report the direct transmission of a natural classical scrapie isolate to cynomolgus macaque, a highly 
relevant model for human prion diseases, after a 10-year silent incubation period, with features 
similar to those reported for human cases of sporadic CJD. Scrapie is thus actually transmissible to 
primates with incubation periods compatible with their life expectancy, although fourfold longer 
than BSE. Long-term experimental transmission studies are necessary to better assess the zoonotic 
potential of other prion diseases with high prevalence, notably Chronic Wasting Disease of deer and 
elk and atypical/Nor98 scrapie.
For several protein-misfolding neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, 
prion diseases, amyotrophic lateral sclerosis, etc.), a minority of cases are linked to mutations of specific 
proteins (familial cases, approximately 10%) but the great majority are considered to be sporadic and idi-
opathic, i.e. without identified origin. Among these proteinopathies, prion diseases constitute a peculiar 
group as they naturally occur in both humans and animals and are transmissible through natural routes 
of exposure. In humans, Kuru was transmitted through cannibalistic funeral rites1 and Creutzfeldt-Jakob 
disease (CJD) has been transmitted iatrogenically from the use of growth hormone, grafts, or surgi-
cal instruments contaminated with tissue from unidentified human sporadic CJD cases2. Sporadic CJD 
(sCJD) represents more than 80% of human cases of prion disease and is readily transmissible to humans 
and non-human primates.
In animals, classical scrapie (c-scrapie) of sheep and goats and chronic wasting disease (CWD) in 
farmed and wild cervids are transmitted through direct contact between animals and through grazing in 
prion-contaminated environments, which leads to persistence of these diseases at an enzootic level. In 
contrast, the bovine spongiform encephalopathy (BSE, hereafter called classical BSE, or c-BSE) epizootic 
was maintained through feeding cattle with prion-contaminated meat and bone meals.
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Animal prion diseases were considered to be innocuous for humans until the diagnosis of the first 
cases of variant CJD in young British patients3, which were linked to the consumption of beef products 
derived from c-BSE-infected cattle. This interspecies transmission was first hypothesized on the basis of 
epidemiological evidence (the occurrence of all the first human vCJD cases in the country hosting more 
than 99% of the cattle c-BSE cases) and later confirmed by experimental transmissions in animal models 
(macaque4 and mice5). Several strict control measures for c-BSE were successfully adopted in Europe to 
protect human and animal health during past decades, and were extended to other animal prion diseases 
such as scrapie. Due to a decreasing prevalence of c-BSE to a point where only rare cases are reported, 
control measures are being progressively challenged and relaxed.
Prior to the recognition of c-BSE, c-scrapie and sCJD were the main reported prion diseases. The 
long-held belief that scrapie does not transmit to humans has been based on the lack of significant spatial 
correlation between c-scrapie and sCJD clusters6,7 and the fact that Australia and New Zealand, which 
are nearly free from c-scrapie, have a similar prevalence of sCJD as countries with scrapie cases. On the 
basis of these epidemiological considerations, c-scrapie was considered unrelated to sCJD and harmless 
to humans. The emergence of c-BSE dramatically increased the number of studies in the prion field: 
new prion diseases were identified in both animals and humans, and improved molecular and lesional 
discrimination approaches provided evidence that several different prion strains or phenotypes could be 
grouped under the terminologies of “classical scrapie” or “sporadic CJD”. Therefore, it appears obvious 
that global epidemiological studies devoid of fine discrimination between those different animal and 
human prion strains would be unable to highlight and identify if a particular animal prion strain could 
have a potential zoonotic effect.
Historical transmission studies of scrapie to primates have shown variable results1,8–10, leading to the 
generally accepted notion that, as of yet, there was no clear experimental evidence that scrapie prions are 
associated with prion disease in humans11, even if the species barrier from humans to small ruminants 
can be crossed since sCJD induces a scrapie-like prion disease in goats12. Very recently, several scrapie 
isolates have been shown to induce prion diseases with phenotypic features similar to sporadic CJD in 
transgenic mice overexpressing human PrP13. This recent study provides clear evidence that scrapie has 
at least a zoonotic potential, even though transmissions occurred at a low rate after a second passage 
in this rodent model considered as highly susceptible based on the overexpression of human PrP. These 
observations question the real level of permeability of the human species barrier with regards to scrapie 
transmission in physiological conditions of PrP expression and the true level of the zoonotic potential 
of the different scrapie agents.
Transgenic mouse models of human prion diseases complement studies performed in different species 
of non-human primates, the latter model providing the first evidence of human prion disease trans-
mission1,4,9. Among old-world primates, which are closest to humans in terms of phylogeny, the cyno-
molgus macaque is the preferred current primate model for the study of human prion diseases4,14–16. 
Interestingly, the recent mathematical modeling of vCJD infection based on this model fits well with the 
current human epidemiology of vCJD17,18.
We, and others, have used the macaque model to assess the zoonotic potential of other ruminant 
prion strains in comparison to c-BSE. The more recently identified atypical L-type BSE strain was also 
transmissible to macaques19,20 even apparently more efficiently than c-BSE, corroborating other experi-
mental models21,22.
The successful transmission of two bovine prion strains into macaques after relatively short incu-
bation periods was suggestive of a low cattle-to-primate species barrier and we have thus continued to 
explore the zoonotic potential of cattle-derived prion isolates (including CWD after passage through 
cattle). As controls, we used two sheep prion isolates (one c-scrapie and one atypical/Nor98 scrapie) 
both reputed to be non-transmissible and devoid of risk to humans. We report here that, surprisingly, the 
isolate of sheep c-scrapie led to clinical prion disease in a cynomolgus macaque a decade after exposure 
(two to four times longer than the incubation period observed with bovine prion strains) indicating the 
need for continued research in this area to clarify any potential risks of scrapie to human health and 
implying that very long term experiments are necessary to properly assess this risk.
Results
We inoculated cynomolgus macaques through the intracerebral route with different inocula of animal 
prion diseases. For some of them, inoculation in tonsils also was performed to model oral exposure. The 
survival periods are shown in table I and compared to the results of c-BSE and L-type BSE experiments 
previously described by our and other groups, including oral exposures14,16,19,20,23,24. C-BSE inoculated 
macaques developed disease from 2 to 8 years (93 months) post-inoculation, depending on the dose 
(25 mg to 50 μ g of brain for the lowest doses which transmitted the disease). No further prion disease 
was observed within c-BSE inoculated macaques for the following four years (ongoing study, 12 years 
of surveillance). However, one cynomolgus macaque exhibited obvious neurological signs more than 9 
years (110 months) after intracerebral exposure to a high dose of a sheep classical scrapie isolate (25 mg 
of brain). The animal presented with an anxious/nervous disposition, hyperesthesia, and a stiff gait. 
Trembling of the forelegs when catching objects or food progressively worsened. Weakness was first 
noted in the right leg and then progressed to both legs together with ataxia and general weakness. After 
8 months of clinical progression, the animal was euthanized 118 months post-inoculation.
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At postmortem examination, the brain was atrophic, most evident in the temporal lobes (Fig.  1A). 
Microscopic examination revealed widespread spongiform change throughout the nervous system, with 
a distribution of spongiform lesions different from those observed for c-BSE- or L-type BSE-infected 
macaques (Fig.  2). Lesions were irregularly laminar in the neocortex and more intense in the cingu-
lar and occipital lobes (Fig. 1B and 1I compared to 1J), moderate in striatum, thalamus, hippocampus 
and brain stem with a dorsal predominance, and very mild in the spinal cord except at the lumbar 
level. There was no vacuolation in lateral cuneate nucleus or the nucleus of the vagus nerve. Conversely, 
in the cerebellum, spongiosis of the Purkinje cells was so intense that most of them were destroyed 
(Fig. 1C). Elsewhere, neuronal loss was moderate, increasing from frontal to occipital cortex. Mild neu-
ronal loss also was present in the basal ganglia and the amygdala. Shrunken neurons were noted in 
entorhinal cortex, subiculum, field CA2 of the hippocampus associated with an axonal loss in temporal 
lobe (Fig. 1D,E), substantia nigra and locus coeruleus. Optic tracts were practically normal. No long tract 
degeneration was observed.
A peculiar lesion was present in the medial nucleus of the thalamus including a massive loss of 
parenchymal elements associated with spongiform change and gliosis (Fig. 1F & 1G vs 1H) but devoid 
Figure 1. Neuropathological features of scrapie-infected cynomolgus macaque. (A) Macroscopic view of 
brain atrophy predominant in temporal lobe and enlarged ventricles, associated with a half-turn rotation of 
the hippocampal formation (x 1.4, Klüver-Barrera (KB) stain). (B) Laminar spongiform change involving 
mostly layer IV of occipital cortex (x 100 original magnification, Hematoxylin-Eosin (HE)). (C) Spongiform 
change in Purkinje cells of the cerebellar cortex, most of them being shrunken or absent (x 400, KB). (D) 
Axonal loss of the temporal white matter, visualized with monoclonal anti-neurofilament antibody 2F11 (x 
400, 2F11 antibody), in comparison to (E) a normal neurofilament staining in temporal white matter of a 
healthy primate (x 400). (F) Massive lesion of the dorso-medialis thalamic nucleus (x 25, KB) (G) Higher 
magnification of the thalamic nucleus (corresponding to the inset in panel (F) showing massive rarefaction 
of neurons (arrows marked the few remaining neurons), an increase of the density of glia and spongiosis (x 
400, KB), in comparison to (H) the same thalamic region in healthy primate. (I) Higher magnification of 
the laminar spongiosis of occipital cortex (x200, HE), in comparison to (J) the occipital cortex of healthy 
primate (x200, HE). (K) Iron deposits in the globus pallidus (x 400, Perls).
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of necrosis or evidence of a vascular abnormality. The mammillary body had spongiform change, but 
no obvious neuronal loss was observed and the width of the corpus callosum was within normal limits.
Gliosis was present in the hemispheric white matter, the pars lateralis of the globus pallidus, the 
brain stem and the lower spinal cord. Reactive astrocytosis was especially intense in the cerebellum. Iron 
deposits were noted in the lenticular nucleus, predominant in globus pallidus (Fig. 1K).
PrPSc immunoreactivity was heavily distributed in cortex, striatum and cerebellum, consisting of 
synaptic deposits and small and large aggregates (Fig.  3A,B,C,D), whereas PrPC was undetected with 
this technique (supplementary figure 1). Deposits were predominant in the cingular and occipital cor-
tices, the basal ganglia, and the molecular layer of the cerebellum, and mild in the brainstem and the 
spinal cord. In the field CA2 of the hippocampus, large aggregates were correlated with neuronal loss 
(Figs  3E,F). PrPSc immunoreactivity was also present in the plexiform layers of the retina (data not 
Figure 2. Spongiform lesion profiles in primates infected with various TSEs. Lesion profiles in primates 
exposed to scrapie (A) BSE (B) or L-type BSE (C) were defined according to the scoring and areas described 
by Parchi et al.29. The lesion profile of c-BSE- and L-type BSE-infected primates is depicted as the mean 
among 5 and 4 primates exposed to c-BSE or L-type BSE, respectively.
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shown). According to the cerebral atrophy, Alzheimer’s markers were also investigated but were negative 
(data not shown).
Western blot analyses confirmed that there were lower amounts of PrPres in brainstem in comparison 
to the cerebral cortices or cerebellum (Fig. 4). The molecular profile of all western blot samples exhibited 
PrPres with a type 1 profile characterized by a 21 kDa unglycosylated band revealed with Sha-31 anti-PrP 
antibody, whereas the samples derived from c-BSE- and L-type BSE-infected primates exhibited PrPres 
with a type 2 profile (19 kDa) as expected. Moreover, the N-terminal part of PrPres was resistant to strin-
gent conditions of proteolysis in brain material derived from the scrapie-infected macaque, as revealed 
with SAF-32 anti-PrP antibody: this is in contrast to PrPres derived from c-BSE or L-type BSE-infected 
animals. We did not detect accumulation of PrPres in peripheral organs (lymph nodes, spleen, tonsils) of 
this animal exposed through the intracerebral route.
At the time of this writing, the macaque exposed to the atypical (Nor98) scrapie isolate remains 
asymptomatic (> 7 years post-inoculation). Similarly, we have not observed clinical signs in three 
macaques exposed to CWD isolates derived from naturally infected white-tailed deer or experimentally 
infected cattle (7 years post-inoculation). Amongst bovine prion strains, classical BSE (intracerebrally 
inoculated) induced prion disease was observed in 17 macaques after incubation periods ranging from 
Figure 3. PrPsc immunostaining of CNS of scrapie-infected cynomolgus macaque. (A) Massive laminar 
PrPSc immunoreactivity in layers IV and VI of occipital cortex with many aggregates after PK treatment (x 
50- 3F4 monoclonal antibody). (B) Predominance of PrPSc in the superficial layers of the frontal cortex, on 
top of underlying columns (x 25- 3F4). (C) Detail of PrPsc immunoreactivity in the frontal cortex (x100- 
3F4). (D) PrPSc synaptic deposits and aggregates in molecular and granule cell layers of cerebellar cortex (x 
400- 3F4). (E) Ammon’s horn immunostaining showing deposits of PrPSc in pyramidal cells and abundant 
aggregates in field CA2 (x 25- 12F10 monoclonal antibody). (F) Detail of the aggregates in field CA2 
(x100 – 3F4) (G) PrPSc immunostaining marked in striatum while mild in globus pallidus (x 12.5-3F4). (H) 
Immunostaining with polyclonal cytochrome c oxidase antibody with strong immunoreactivity within the 
neuropil of the putamen (x12.5 -gift of Dr A.Lombes). (I) Absence of PrPC staining in the occipital cortex of 
an healthy control (x100 – 3F4).
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6Scientific RepoRts | 5:11573 | DOi: 10.1038/srep11573
about three to less than 8 years depending on the dose inoculated (100 mg to 50 μ g), whereas 2.5 to 25 mg 
of brain tissue of L-type BSE intracerebrally inoculated into macaques resulted in an incubation period 
of 2 years. More than 10 years post-inoculation, an H-type BSE-exposed macaque also remains without 
neurological signs (Table 1).
Discussion
We describe the transmission of spongiform encephalopathy in a non-human primate inoculated 10 
years earlier with a strain of sheep c-scrapie. Because of this extended incubation period in a facility 
in which other prion diseases are under study, we are obliged to consider two alternative possibilities 
that might explain its occurrence. We first considered the possibility of a sporadic origin (like CJD in 
humans). Such an event is extremely improbable because the inoculated animal was 14 years old when 
the clinical signs appeared, i.e. about 40% through the expected natural lifetime of this species, compared 
to a peak age incidence of 60–65 years in human sporadic CJD, or about 80% through their expected 
lifetimes. Moreover, sporadic disease has never been observed in breeding colonies or primate research 
laboratories, most notably among hundreds of animals over several decades of study at the National 
Institutes of Health25, and in nearly twenty older animals continuously housed in our own facility.
The second possibility is a laboratory cross-contamination. Three facts make this possibility equally 
unlikely. First, handling of specimens in our laboratory is performed with fastidious attention to the 
avoidance of any such cross-contamination. Second, no laboratory cross-contamination has ever been 
documented in other primate laboratories, including the NIH, even between infected and uninfected 
animals housed in the same or adjacent cages with daily intimate contact (P. Brown, personal communi-
cation). Third, the cerebral lesion profile is different from all the other prion diseases we have studied in 
this model19, with a correlation between cerebellar lesions (massive spongiform change of Purkinje cells, 
intense PrPres staining and reactive gliosis26) and ataxia. The iron deposits present in the globus pallidus 
are a non specific finding that have been reported previously in neurodegenerative diseases and aging27. 
Conversely, the thalamic lesion was reminiscent of a metabolic disease due to thiamine deficiency28 
but blood thiamine levels were within normal limits (data not shown). The preferential distribution of 
spongiform change in cortex associated with a limited distribution in the brainstem is reminiscent of the 
lesion profile in MM2c and VV1 sCJD patients29, but interspecies comparison of lesion profiles should be 
interpreted with caution. It is of note that the same classical scrapie isolate induced TSE in C57Bl/6 mice 
with similar incubation periods and lesional profiles as a sample derived from a MM1 sCJD patient30.
Figure 4. PrPres electrophoretic profile in scrapie-infected macaque. Samples issued from different brain 
regions of the scrapie-infected macaque (frontal, occipital, cerebellum or obex) were homogenized (20% 
weight/volume in 5% glucose solution) and then purified according to the TeSeE purification protocol using 
4 μ g of proteinase K / mg of brain19. As controls, samples derived from occipital cortices of patients (healthy, 
MM1 or MM2c sporadic CJD, variant of CJD) or classical BSE- or L-type BSE-infected macaques were 
equally treated. Resulting purified PrPres was solubilized in loading buffer, the equivalent of 0.3 to 1,500 μ g 
of brain was loaded on a 12% acrylamide gel (depending on the levels of positivity of each sample), and 
revealed using anti-PrP monoclonal antibodies targeted against the core (Sha-31 recognizing epitope 145–
152) or the octapeptides (SAF-32, recognizing octarepeats included in region 57–88) of the protein.
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We are therefore confident that the illness in this cynomolgus macaque represents a true transmission 
of a sheep c-scrapie isolate directly to an old-world monkey, which taxonomically resides in the primate 
subdivision (parvorder of catarrhini) that includes humans. With an homology of its PrP protein with 
humans of 96.4%31, cynomolgus macaque constitutes a highly relevant model for assessing zoonotic risk 
of prion diseases. Since our initial aim was to show the absence of transmission of scrapie to macaques 
in the worst-case scenario, we obtained materials from a flock of naturally-infected sheep, affecting ani-
mals with different genotypes32. This c-scrapie isolate exhibited complete transmission in ARQ/ARQ 
sheep (332 ± 56 days) and Tg338 transgenic mice expressing ovine VRQ/VRQ prion protein (220 ± 5 
days) (O. Andreoletti, personal communication). From the standpoint of zoonotic risk, it is important 
to note that sheep with c-scrapie (including the isolate used in our study) have demonstrable infectivity 
throughout their lymphoreticular system early in the incubation period of the disease (3 months-old 
for all the lymphoid organs, and as early as 2 months-old in gut-associated lymph nodes)33. In addition, 
scrapie infectivity has been identified in blood34, milk35 and skeletal muscle36 from asymptomatic but 
scrapie infected small ruminants which implies a potential dietary exposure for consumers.
Two earlier studies have reported the occurrence of clinical TSE in cynomolgus macaques after 
exposures to scrapie isolates. In the first study, the “Compton” scrapie isolate (derived from an English 
sheep) and serially propagated for 9 passages in goats did not transmit TSE in cynomolgus macaque, 
rhesus macaque or chimpanzee within 7 years following intracerebral challenge1; conversely, after 8 
supplementary passages in conventional mice, this “Compton” isolate induced TSE in a cynomolgus 
macaque 5 years after intracerebral challenge, but rhesus macaques and chimpanzee remained asympto-
matic 8.5 years post-exposure8. However, multiple successive passages that are classically used to select 
laboratory-adapted prion strains can significantly modify the initial properties of a scrapie isolate, thus 
questioning the relevance of zoonotic potential for the initial sheep-derived isolate. The same isolate 
had also induced disease into squirrel monkeys (new-world monkey)9. A second historical observation 
reported that a cynomolgus macaque developed TSE 6 years post-inoculation with brain homogenate 
from a scrapie-infected Suffolk ewe (derived from USA), whereas a rhesus macaque and a chimpanzee 
exposed to the same inoculum remained healthy 9 years post-exposure1. This inoculum also induced TSE 
in squirrel monkeys after 4 passages in mice. Other scrapie transmission attempts in macaque failed but 
had more shorter periods of observation in comparison to the current study. Further, it is possible that 
there are differences in the zoonotic potential of different scrapie strains.
The most striking observation in our study is the extended incubation period of scrapie in the 
macaque model, which has several implications. Firstly, our observations constitute experimental evi-
dence in favor of the zoonotic potential of c-scrapie, at least for this isolate that has been extensively 
studied32–36. The cross-species zoonotic ability of this isolate should be confirmed by performing dupli-
cate intracerebral exposures and assessing the transmissibility by the oral route (a successful transmis-
sion of prion strains through the intracerebral route may not necessarily indicate the potential for oral 
transmission37). However, such confirmatory experiments may require more than one decade, which is 
Table 1. Survival periods of cynomolgus macaques exposed to different agents of animal prion 
diseases. Macaques were inoculated through the intracerebral route (+ 8 mg through intratonsilar route 
(ito) *) or the oral route with various amounts of brain derived from ruminants affected with TSEs (MD: 
Mule deer; WTD: white-tailed deer). Survival periods are in months post-inoculation. To provide context 
for the results of the present study this table includes the data from studies conducted by other groups. 
1Holznagel et al. 201323. 2Lasmezas et al. 200514. 3Montag et al. 201324. 4Ono et al. 201116. 5Comoy et al. 
200819. 6Ono et al. 201120.
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hardly compatible with current general management and support of scientific projects; thus this study 
should be rather considered as a case report.
Secondly, transmission of c-BSE to primates occurred within 8 years post exposure for the lowest 
doses able to transmit the disease (the survival period after inoculation is inversely proportional to the 
initial amount of infectious inoculum). The occurrence of scrapie 10 years after exposure to a high dose 
(25 mg) of scrapie-infected sheep brain suggests that the macaque has a higher species barrier for sheep 
c-scrapie than c-BSE, although it is notable that previous studies based on in vitro conversion of PrP 
suggested that BSE and scrapie prions would have a similar conversion potential for human PrP38.
Thirdly, prion diseases typically have longer incubation periods after oral exposure than after intracer-
ebral inoculations: since humans can develop Kuru 47 years after oral exposure39, an incubation time of 
several decades after oral exposure to scrapie would therefore be expected, leading the disease to occur 
in older adults, i.e. the peak age for cases considered to be sporadic disease, and making a distinction 
between scrapie-associated and truly sporadic disease extremely difficult to appreciate.
Fourthly, epidemiologic evidence is necessary to confirm the zoonotic potential of an animal disease 
suggested by experimental studies. A relatively short incubation period and a peculiar epidemiological 
situation (e.g., all the first vCJD cases occurring in the country with the most important ongoing c-BSE 
epizootic) led to a high degree of suspicion that c-BSE was the cause of vCJD. Sporadic CJD are con-
sidered spontaneous diseases with an almost stable and constant worldwide prevalence (0.5–2 cases per 
million inhabitants per year), and previous epidemiological studies were unable to draw a link between 
sCJD and classical scrapie6,7,40,41, even though external causes were hypothesized to explain the occur-
rence of some sCJD clusters42–44. However, extended incubation periods exceeding several decades would 
impair the predictive values of epidemiological surveillance for prion diseases, already weakened by a 
limited prevalence of prion diseases and the multiplicity of isolates gathered under the phenotypes of 
“scrapie” and “sporadic CJD”.
Fifthly, considering this 10 year-long incubation period, together with both laboratory and epidemi-
ological evidence of decade or longer intervals between infection and clinical onset of disease, no pre-
mature conclusions should be drawn from negative transmission studies in cynomolgus macaques with 
less than a decade of observation, as in the aforementioned historical transmission studies of scrapie to 
primates1,8,9. Our observations and those of others45,46 to date are unable to provide definitive evidence 
regarding the zoonotic potential of CWD, atypical/Nor98 scrapie or H-type BSE. The extended incu-
bation period of the scrapie-affected macaque in the current study also underscores the limitations of 
rodent models expressing human PrP for assessing the zoonotic potential of some prion diseases since 
their lifespan remains limited to approximately two years21,47,48. This point is illustrated by the fact that 
the recently reported transmission of scrapie to humanized mice was not associated with clinical signs 
for up to 750 days and occurred in an extreme minority of mice with only a marginal increase in attack 
rate upon second passage13. The low attack rate in these studies is certainly linked to the limited lifespan 
of mice compared to the very long periods of observation necessary to demonstrate the development of 
scrapie. Alternatively, one could estimate that a successful second passage is the result of strain adapta-
tion to the species barrier, thus poorly relevant of the real zoonotic potential of the original scrapie isolate 
of sheep origin49. The development of scrapie in this primate after an incubation period compatible with 
its lifespan complements the study conducted in transgenic (humanized) mice; taken together these 
studies suggest that some isolates of sheep scrapie can promote misfolding of the human prion protein 
and that scrapie can develop within the lifespan of some primate species.
In addition to previous studies on scrapie transmission to primate1,8,9 and the recently published study 
on transgenic humanized mice13, our results constitute new evidence for recommending that the poten-
tial risk of scrapie for human health should not be dismissed. Indeed, human PrP transgenic mice and 
primates are the most relevant models for investigating the human transmission barrier. To what extent 
such models are informative for measuring the zoonotic potential of an animal TSE under field expo-
sure conditions is unknown. During the past decades, many protective measures have been successfully 
implemented to protect cattle from the spread of c-BSE, and some of these measures have been extended 
to sheep and goats to protect from scrapie according to the principle of precaution. Since cases of c-BSE 
have greatly reduced in number, those protective measures are currently being challenged and relaxed in 
the absence of other known zoonotic animal prion disease. We recommend that risk managers should 
be aware of the long term potential risk to human health of at least certain scrapie isolates, notably for 
lymphotropic strains like the classical scrapie strain used in the current study. Relatively high amounts 
of infectivity in peripheral lymphoid organs in animals infected with these strains could lead to contam-
ination of food products produced for human consumption. Efforts should also be maintained to further 
assess the zoonotic potential of other animal prion strains in long-term studies, notably lymphotropic 
strains with high prevalence like CWD, which is spreading across North America, and atypical/Nor98 
scrapie (Nor98)50 that was first detected in the past two decades and now represents approximately half 
of all reported cases of prion diseases in small ruminants worldwide, including territories previously 
considered as scrapie free. Even if the prevailing view is that sporadic CJD is due to the spontaneous 
formation of CJD prions, it remains possible that its apparent sporadic nature may, at least in part, result 
from our limited capacity to identify an environmental origin.
www.nature.com/scientificreports/
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Materials and Methods
Ethics statement. Primates were housed and handled in accordance with the European Directive 
2010/63 related to animal protection and welfare in research, under constant internal surveillance of 
veterinarians. Animals were handled under anesthesia to limit stress, and euthanasia was performed for 
ethical reasons when animals lost autonomy. All the experimental protocols were approved by the French 
Atomic Energy Commission Ethical Committee (CETEA, approval 12-047).
Experimental animals. Captive-bred 2–5 year-old male cynomolgus macaques (Macaca fascicularis) 
were provided by Noveprim (Mauritius), checked for the absence of common primate pathogens before 
importation, and handled in accordance to national guidelines. They were all homozygous for methio-
nine at PRNP codon 129. Life expectancy of cynomolgus macaques in captivity is 35 to 39 years. Animals 
housed in level-3 animal care facilities (agreement numbers A 92-032-02 for animal care facilities, 92-189 
for animal experimentation) were daily controlled by animal caretaker and regularly examined at least 
once a week by veterinarians.
Experimental inoculations. The classical scrapie inoculum was derived from the cerebellum of a 
French Romanov sheep (ARQ/ARQ homozygote at codons 136, 154 and 171 for PrP gene) naturally 
infected with classical scrapie (21 kDa PrPres), and the atypical scrapie (Nor98) inoculum was derived 
from the cerebellum of a Norwegian sheep naturally infected with Nor98 (ARQ/ARR). The cattle-derived 
inocula were issued from a pool of 11 naturally infected UK cattle (c-BSE)51, an Italian natural case 
(L-type BSE, case #108852) or a French natural case (H-type BSE, case #A1F53). The CWD-related inocula 
were derived from either experimentally infected cattle (case #599 infected with mule deer (MD)-derived 
CWD or case #611 infected with white-tailed deer (WTD)-derived CWD54,55), or directly from infected 
white-tailed deer (case #654 from the same experiments).
These samples were homogenized (10% weight/volume) in a 5% glucose solution, and the equivalent 
of 2.5 to 100 mg of brain inocula were intracerebrally (i.c.) inoculated to macaques under anesthesia. 
When specified, the equivalent of 8 mg of brain inocula was injected into tonsils (intratonsilar, i.to) to 
model a peripheral exposure. Inoculation were performed according procedures established to avoid 
any cross-contamination (inoculation of unique inoculum at a single time, use of disposable materials, 
systematic double checking).
Neuropathology and immunohistochemistry. Tissues were fixed in 10% formalin for process-
ing for microscopic examination. Neuropathological methods and immunohistochemical detection of 
pathological prion protein (PrPsc) were performed on brain sections as previously described56. Briefly, 
PrP was detected using the Discovery Automated IHC Stainer. After dewaxing with Ventana EZ Prep 
solution, slides were sequentially incubated with the cell conditioner 1 protocol (CC1) for 48 minutes, 
guanidinium thiocyanate 4.0 M for 16 minutes, the primary mouse monoclonal antibody (3F4 or 12F10) 
for 40 minutes, the secondary anti-mouse antibody OmniMap anti-Ms HRP (Ventana) for 16 minutes. 
Reactions were developed with the ChromoMap DAB kit (Ventana).
PrPres analysis. PrPres was purified according to the TeSeE purification protocol (Bio-Rad), in adapted 
conditions of proteolysis for strain discrimination as previously described19, using Sha-31 or SAF-32 
antibodies.
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